Atila EROĞLU, Atila TÜRKYILMAZ, Bülent ALBAYRAK, Yener AYDIN, İbrahim KAPLAN, Betül GÜNDOĞDU

Prognostic importance of serum CRP, prealbumin, and transferrin levels in patients with advanced stage esophageal cancer

Amaç: Bu çalışmada stent takılarak tedavi edilen ileri evre özofagus kanserli hastalarda serum C-reaktif protein (CRP), prealbumin ve transferrin düzeylerinin prognostik değeri araştırıldı. Çalışma planı: Temmuz 2007 ve Aralık 2008 tarihleri arasında gerçekleştirilen prospektif randomize bir çalışmada lokal olarak ilerlemiş hastalık veya uzak organ metastazı nedeniyle stent takılarak tedavi edilen ardışık 61 hastada, stent takılmadan 1-3 gün önce serum CRP, prealbumin ve transferrin düzeyleri çalışıldı. Tüm hastalar ölünceye kadar takip edildi. Bulgular: Stent tüm hastalarda başarı ile takılarak oral alım tekrar sağlandı. İşleme bağlı mortalite gözlenmedi. Hastaların ortalama sağkalım süresi 164.3±120.3 gün (dağılım 15-450 gün) idi. Serum CRP seviyesi ≥10 mg/L olan hastalarda (n=38) ortalama sağkalım 103.2±82.3 gün iken serum CRP seviyesi

İleri evre özofagus kanserli hastalarda serum CRP, prealbumin ve transferrin düzeylerinin prognostik önemi

Background: This study investigated the prognostic value of serum C-reactive protein (CRP), prealbumin, and transferrin levels in patients with advanced stage esophageal cancers treated with stent placement. Methods: In a prospective, randomized study conducted between July 2007 and December 2008, serum CRP, prealbumin, and transferrin levels were determined 1-3 days prior to stent placement in 61 consecutive patients who underwent stent placement due to locally advanced disease or distant organ metastasis. All patients were followed until death. Results: The stent was successfully placed in all patients and oral intake was restored. There was no procedure-related mortality. The mean survival period of the patients was 164.3±120.3 days (range 15 to 450 days). Whereas the mean survival period was 103.2±82.3 days in patients with a serum CRP level ≥10 mg/L (n=38), it was 265.4±121.2 days in patients with a serum CRP level

PDF

___

1. Eroglu A, Turkyilmaz A, Subasi M, Karaoglanoglu N. The use of self-expandable metallic stents for palliative treatment of inoperable esophageal cancer. Dis Esophagus 2010;23:64-70.
2. Guillem P, Triboulet JP. Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis Esophagus 2005;18:146-50.
3. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Aoki T, et al. Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 2003;83:248-52.
4. Gockel I, Dirksen K, Messow CM, Junginger T. Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus. World J Gastroenterol 2006;12:3746-50.
5. Krzystek-Korpacka M, Matusiewicz M, Diakowska D, Grabowski K, Blachut K, Kustrzeba-Wojcicka I, et al. Acute-phase response proteins are related to cachexia and accelerated angiogenesis in gastroesophageal cancers. Clin Chem Lab Med 2008;46:359-64.
6. Rivadeneira DE, Evoy D, Fahey TJ 3rd, Lieberman MD, Daly JM. Nutritional support of the cancer patient. CA Cancer J Clin 1998;48:69-80.
7. Habif S. Acute phase proteins in the inflammatory response. İzmir Atatürk Eğitim Hastanesi Tıp Dergisi 2005;43:55-65.
8. Ljungberg B, Grankvist K, Rasmuson T. Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. Eur J Cancer 1997;33:1794-8.
9. Nozoe T, Saeki H, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg 2001;182:197-201.
10. Guerra LT, Rosa AR, Romani RF, Gurski RR, Schirmer CC, Kruel CD. Serum transferrin and serum prealbumin as markers of response to nutritional support in patients with esophageal cancer. Nutr Hosp 2009;24:241-2.
11. Palesty JA, Dudrick SJ. What we have learned about cachexia in gastrointestinal cancer. Dig Dis 2003;21:198-213.
12. Saini A, Al-Shanti N, Stewart CE. Waste management - cytokines, growth factors and cachexia. Cytokine Growth Factor Rev 2006;17:475-86.
13. Argilés JM, Busquets S, López-Soriano FJ. Cytokines as mediators and targets for cancer cachexia. Cancer Treat Res 2006;130:199-217.
14. Loberg RD, Bradley DA, Tomlins SA, Chinnaiyan AM, Pienta KJ. The lethal phenotype of cancer: the molecular basis of death due to malignancy. CA Cancer J Clin 2007;57:225-41.
15. Krzystek-Korpacka M, Matusiewicz M, Diakowska D, Grabowski K, Blachut K, Kustrzeba-Wojcicka I, et al. Impact of weight loss on circulating IL-1, IL-6, IL-8, TNF-alpha, VEGF-A, VEGF-C and midkine in gastroesophageal cancer patients. Clin Biochem 2007;40:1353-60
16. Fearon KC, Voss AC, Hustead DS; Cancer Cachexia Study Group. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 2006;83:1345-50.
17. Lelbach A, Muzes G, Feher J. Current perspectives of catabolic mediators of cancer cachexia. Med Sci Monit 2007;13:RA168-173.
18. Le Moullac B, Gouache P, Bleiberg-Daniel F. Regulation of hepatic transthyretin messenger RNA levels during moderate protein and food restriction in rats. J Nutr 1992;122:864-70.
19. Beck FK, Rosenthal TC. Prealbumin: a marker for nutritional evaluation. Am Fam Physician 2002;65:1575-8.
20. Elhasid R, Laor A, Lischinsky S, Postovsky S, Weyl Ben Arush M. Nutritional status of children with solid tumors. Cancer 1999;86:119-25.
21. Malvy DJ, Arnaud J, Burtschy B, Sommelet D, Leverger G, Dostalova L, et al. Antioxidant micronutrients and childhood malignancy during oncological treatment. Med Pediatr Oncol 1997;29:213-7.